Hot Features
Premium
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| NexImmune Inc | NEXI | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 3.36 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 3.36 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 1.2501 - 28.405 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 3.36 | USD |
NexImmune Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 3.56M | 1.06M | - | 0 | -32.34M | -30.57 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
NexImmune News
| Date | Time | Source | News Article |
|---|---|---|---|
| 3/07/2024 | 12:20 | Business Wire | Konzernergebnis zum 31. Dezember 2023 genehmigt, starke.. |
| 3/07/2024 | 11:33 | Business Wire | Approbation des résultats financiers du groupe au 31.. |
| 3/07/2024 | 00:31 | Business Wire | Approvati i risultati finanziari di Gruppo al 31 dicembre.. |
| 3/07/2024 | 00:30 | Business Wire | Group Financial Results as of December 31st 2023 Approved,.. |
| 2/06/2024 | 15:42 | GlobeNewswire Inc. | NexImmune Announces Closing of $3.67 Million Registered.. |
| 2/06/2024 | 15:30 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting.. |
| 2/05/2024 | 16:10 | Edgar (US Regulatory) | Form 8-K - Current report |
| 2/05/2024 | 15:34 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] |
| 2/02/2024 | 13:00 | GlobeNewswire Inc. | NexImmune Announces $3.67 Million Registered Direct Offering.. |
| 2/02/2024 | 12:25 | Edgar (US Regulatory) | Form 8-K - Current report |
| 2/01/2024 | 08:17 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/19/2024 | 15:43 | Edgar (US Regulatory) | Form 8-K - Current report |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NEXI Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.48 | 3.587 | 3.24 | 3.31 | 8,471 | -0.12 | -3.45% |
| 1 Month | 5.36 | 5.3823 | 3.01 | 3.88 | 36,424 | -2.00 | -37.31% |
| 3 Months | 10.46 | 10.9999 | 3.01 | 6.73 | 76,724 | -7.10 | -67.88% |
| 6 Months | 3.61 | 28.405 | 1.2501 | 8.55 | 1,268,292 | -0.25 | -6.93% |
| 1 Year | 9.25 | 28.405 | 1.2501 | 8.49 | 720,132 | -5.89 | -63.68% |
| 3 Years | 479.75 | 497.50 | 1.2501 | 27.91 | 554,114 | -476.39 | -99.30% |
| 5 Years | 575.25 | 695.00 | 1.2501 | 36.93 | 525,061 | -571.89 | -99.42% |
NexImmune Description
| NexImmune Inc is a clinical-stage biotechnology company engaged in developing immunotherapy to employ the body's T cells to generate an immune response that mimics natural biology. It creates therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. |
